Jintrolong® PEG-SOMATROPIN from GenSci highlighted at ECE 2024

Time

2024-05-17

Readership

239

Share

At the 26th European Congress of Endocrinology (ECE2024), the largest endocrine event in Europe, taking place in Stockholm, Sweden, Jintrolong® PEG-SOMATROPIN, developed by GenSci, was highlighted during the Growth Hormone Research Society (GRS) symposium. This symposium featured clinical applications and exploration of long-acting growth hormone (LAGH).

image.png

During the event, Professor Luo Xiaoping from Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology in China shared significant progress in the application of LAGH for children with short stature. In his speech on his experiences with LAGH in children, he underscored the critical role of LAGH in improving patient compliance and convenience by reducing the frequency of injections.

He highlighted, China's unique LAGH product, Jintrolong® PEG-SOMATROPIN from GenSci, is the sole long-acting growth hormone available in the Chinese market and has accumulated tens of thousands of clinical cases, which has shown remarkable efficacy and safety in treating various growth-related conditions such as Growth Hormone Deficiency (GHD), Idiopathic Short Stature (ISS), Small for Gestational Age (SGA), and Turner Syndrome (TS).

Notably, LAGH is currently recommended as a treatment option in China's guidelines for growth hormone dificiency.

image.png

Jintrolong® PEG-SOMATROPIN, developed by GenSci in 2014, is recognized as the world's first long-acting growth hormone (LAGH) injection. Since then, GenSci has been at theforefront of LAGH innovation on a global scale. GenSci takes pride in leveraging LAGH to revolutionize future healthcare and elevate patient care worldwide. The company is dedicated to providing more clinical cases, aiming to advance the industry collaboratively. 

With nearly 30 years of expertise in the field, GenSci has established itself as a pivotal player in LAGH, being Asia's largest manufacturer of recombinant human growth hormone and the exclusive global provider of a comprehensive range of such products. Our products are positively impacting lives in over 10 countries, including key markets such as China, Southeast Asia, the Middle East, South America, and South Africa.